Journal of Neurology

, Volume 261, Issue 1, pp 144–151 | Cite as

Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study

  • François Mouton-Liger
  • David Wallon
  • Anne-Cécile Troussière
  • Rachida Yatimi
  • Julien Dumurgier
  • Eloi Magnin
  • Vincent de la Sayette
  • Emannuelle Duron
  • Nathalie Philippi
  • Emilie Beaufils
  • Audrey Gabelle
  • Bernard Croisile
  • Philippe Robert
  • Florence Pasquier
  • Didier Hannequin
  • Jacques Hugon
  • Claire Paquet
Original Communication


CSF biomarkers of Alzheimer’s disease are well validated in clinical research; however, their pragmatic utility in daily practice is still unappreciated. These biomarkers are used in routine practice according to Health Authority Recommendations. In 604 consecutive patients explored for cognitive disorders, questionnaires were prospectively proposed and filled. Before and after CSF biomarker results, clinicians provided a diagnosis and an estimate of their diagnostic confidence. Analysis has compared the frequency of diagnosis before and after CSF biomarker results using the net reclassification improvement (NRI) method. We have evaluated external validity comparing with data of French Bank National of AD (BNA). A total of 561 patients [Alzheimer’s disease (AD), n = 253; non-AD, n = 308] were included (mean age, 68.6 years; women, 52 %). Clinically suspected diagnosis and CSF results were concordant in 65.2 % of cases. When clinical hypothesis and biological results were discordant, a reclassification occurred in favour of CSF biomarkers results in 76.9 %. The NRI was 39.5 %. In addition, the results show a statistically significant improvement in clinician confidence for their diagnosis. In comparison with BNA data, patients were younger and more frequently diagnosed with AD. Clinicians tend to heavily rely on the CSF AD biomarkers results and are more confident in their diagnoses using CSF AD biomarkers. Thus, these biomarkers appear as a key tool in clinical practice.


Cerebrospinal fluid Biomarkers Alzheimer’s disease Clinical practice 


Amyloid β


Alzheimer disease


Computed tomography


Corticobasal degeneration


Cerebrospinal fluid


Frontotemporal dementia


Lewy body dementia


Lumbar puncture


Mild cognitive impairment


Magnetic resonance imaging


Positron emission tomography


Tau phosphorylated at threonine-181


Single photon emission computed tomography


Total tau



We thank all the patients who were involved in this study and their physicians that accepted to fill in questionnaires that constitute the ISAC network: F. Blanc, MD; B. Crétin MD (University Hospital of Strasbourg, Co-Investigator); L. Volpegillot, MD (Saint-Joseph Hospital, Paris, Co-Investigator); L. Bernard-Bourzeix, MD (University Hospital of Limoges, Co-Investigator); M.N. Cuffi, MD (Castres Hospital; Co-Investigator); A.S. Carret-Rebillat, MD (Leopold Bellan Hospital and Inserm U942, Paris, Co-Investigator); L. Cohen, MD (University Hospital of Grenoble Hospital, Co-Investigator); A. Rollin, MD (University Hospital of Lille, Co-Investigator); F. Lebert MD (University Hospital of Lille, Co-Investigator); M. Sauvée, MD (University Hospital of Nancy, Co-Investigator); O. Vercruysse, MD (University Hospital of Lille, Co-Investigator); O. Hanon MD, PhD; ML. Seux, MD (Univerisity Hospital of Broca APHP, Co-Investigator); E. Dionet MD,(University Hospital of Clermont-Ferrand, Co-Investigator); A. Debart, MD (University Hospital of Reims, Co-Investigator), J. Delrieu, MD (University Hospital of Toulouse, Co-Investigator); O.Dereeper, MD (Calais Hospital, Co-Investigator), J. d’Avigneau (Cholet, Co-investigator). We also thank Joel Ménard, Patrick Trunet, Hervé Maisonneuve for critical revision of the manuscript and statistical advices. We thank Amel Rouis and Roland Chevrier for providing statistical data and analysis from BNA. We thank DIU plan Alzheimer for critical revision and advices.

Conflicts of interest

The study has no sponsor. F. Mouton-Liger, reports no disclosures. D. Wallon received travel expense from Novartis. A.C. Troussiere, Yatimi report no disclosures. J. Dumurgier received travel expense from Novartis. E. Magnin, V. de la Sayette, E. Duron, N. Philippi, E. Beaufils, A. Gabelle, B. Croisile, P. Robert, D. Hannequin report no disclosure. F. Pasquier has received consultancy honorarium from ESAI. Pr. Hugon has received consultancy honorarium from Novartis, Lundbeck. C. Paquet has received travel expense from Novartis.


  1. 1.
    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H (2013) CSF biomarkers for Alzheimer’s pathology and the effect size of APOE epsilon4. Mol Psychiatry. doi: 10.1038/mp.2013.18 PubMedCentralPubMedGoogle Scholar
  3. 3.
    Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 71:266–273PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM, Grossman M (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70:1827–1835PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131–144CrossRefPubMedGoogle Scholar
  6. 6.
    Brunnstrom H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E (2010) Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement 6:104–109CrossRefPubMedGoogle Scholar
  7. 7.
    De Lepeleire J, Wind AW, Iliffe S, Moniz-Cook ED, Wilcock J, Gonzalez VM, Derksen E, Gianelli MV, Vernooij-Dassen M, Interdem G (2008) The primary care diagnosis of dementia in Europe: an analysis using multidisciplinary, multinational expert groups. Aging Ment Health 12:568–576CrossRefPubMedGoogle Scholar
  8. 8.
    Derksen E, Vernooij-Dassen M, Gillissen F, Olde Rikkert M, Scheltens P (2006) Impact of diagnostic disclosure in dementia on patients and carers: qualitative case series analysis. Aging Ment Health 10:525–531CrossRefPubMedGoogle Scholar
  9. 9.
    Dumurgier J, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoc’h K, Schraen S, Sablonniere B, Pasquier F, Touchon J, Lehmann S, Hugon J, Paquet C (2013) Exacerbated CSF abnormalities in younger patients with Alzheimer’s disease. Neurobiol Dis 54:486–491CrossRefPubMedGoogle Scholar
  10. 10.
    Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, Peoc’h K, Schraen S, Pasquier F, Touchon J, Hugon J, Lehmann S, Gabelle A (2012) Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting. Alzheimers Dement 9(4):406–413CrossRefPubMedGoogle Scholar
  11. 11.
    Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc’h K, Schraen S, Buee L, Pasquier F, Hugon J, Touchon J, Lehmann S (2013) Impact of the 2008–2012 French Alzheimer plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM study. J Alzheimers Dis 34:297–305PubMedGoogle Scholar
  12. 12.
    Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Skovronsky DM, Mintun MA, Group AS (2013) Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 27:4–15CrossRefPubMedGoogle Scholar
  13. 13.
    Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P (2010) Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 29:491–497CrossRefPubMedGoogle Scholar
  14. 14.
    Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1143–1153CrossRefPubMedGoogle Scholar
  15. 15.
    Le Duff F, Develay AE, Quetel J, Lafay P, Schuck S, Pradier C, Robert P, French National Alzheimer d (2012) The 2008–2012 French Alzheimer plan: description of the national Alzheimer information system. J Alzheimers Dis 29:891–902PubMedGoogle Scholar
  16. 16.
    Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB (1999) Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 47:564–569CrossRefPubMedGoogle Scholar
  17. 17.
    Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer’s association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7(386–395):e386CrossRefGoogle Scholar
  18. 18.
    Mattsson N, Zetterberg H, Blennow K (2010) Lessons from multicenter studies on CSF biomarkers for Alzheimer’s disease. Int J Alzheimers Dis. doi: 10.4061/2010/610613 Google Scholar
  19. 19.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944CrossRefPubMedGoogle Scholar
  20. 20.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Moons KG, de Groot JA, Linnet K, Reitsma JB, Bossuyt PM (2012) Quantifying the added value of a diagnostic test or marker. Clin Chem 58:1408–1417CrossRefPubMedGoogle Scholar
  22. 22.
    Paquet C, Latour F, Saulnier I, Hanon O (2012) Multicenter study on lumbar puncture indication, clinical practice and feasibility. Rev Neurol (Paris) 168:28–32CrossRefGoogle Scholar
  23. 23.
    Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010) Alzheimer’s disease neuroimaging initiative (ADNI): clinical characterization. Neurology 74:201–209PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Ranginwala NA, Hynan LS, Weiner MF, White CL 3rd (2008) Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry 16:384–388CrossRefPubMedGoogle Scholar
  25. 25.
    Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Martinez Rodriguez, de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372CrossRefPubMedGoogle Scholar
  26. 26.
    Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer’s disease. J Alzheimers Dis 29:171–176PubMedGoogle Scholar
  27. 27.
    Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78:47–54CrossRefPubMedGoogle Scholar
  28. 28.
    Smits LL, Pijnenburg YA, Koedam EL, van der Vlies AE, Reuling IE, Koene T, Teunissen CE, Scheltens P, van der Flier WM (2012) Early onset Alzheimer’s disease is associated with a distinct neuropsychological profile. J Alzheimers Dis 30:101–108PubMedGoogle Scholar
  29. 29.
    Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:652–656CrossRefPubMedGoogle Scholar
  31. 31.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382–389CrossRefPubMedGoogle Scholar
  32. 32.
    Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, Teunissen C, Engelborghs S (2013) Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem 59(4):710–712CrossRefPubMedGoogle Scholar
  33. 33.
    Warren JD, Fletcher PD, Golden HL (2012) The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 8:451–464PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • François Mouton-Liger
    • 1
    • 2
    • 3
  • David Wallon
    • 4
  • Anne-Cécile Troussière
    • 5
  • Rachida Yatimi
    • 6
  • Julien Dumurgier
    • 1
  • Eloi Magnin
    • 7
  • Vincent de la Sayette
    • 8
  • Emannuelle Duron
    • 9
  • Nathalie Philippi
    • 10
  • Emilie Beaufils
    • 11
  • Audrey Gabelle
    • 12
  • Bernard Croisile
    • 13
  • Philippe Robert
    • 6
  • Florence Pasquier
    • 5
  • Didier Hannequin
    • 4
  • Jacques Hugon
    • 1
  • Claire Paquet
    • 1
    • 2
    • 3
  1. 1.Centre Mémoire de Ressources et de Recherche (CMRR) Paris Nord Ile de FranceGroupe hospitalier Lariboisière FW Saint Louis, APHP, Université Paris DiderotParisFrance
  2. 2.Inserm U942ParisFrance
  3. 3.Unité d’Histologie et de Biologie du VieillissementGroupe Hospitalier Lariboisiere FW Saint Louis, APHP, Université Paris DiderotParisFrance
  4. 4.Centre Mémoire (CMRR) and INSERM UMR1079Hôpital Universitaire de RouenRouenFrance
  5. 5.Centre Mémoire (CMRR) de LilleUniversité Lille Nord de France, UDSLLilleFrance
  6. 6.CMRR/EA COBTEK, CHUUniversité de Nice Sophia AntipolisNiceFrance
  7. 7.Centre Mémoire (CMRR) de BesançonHôpital Universitaire de BesançonBesançonFrance
  8. 8.Centre Mémoire (CMRR) de CaenHôpital Universitaire de CaenCaenFrance
  9. 9.Centre Mémoire (CMRR) Paris SudHôpital Broca, APHP, Université Paris VParisFrance
  10. 10.Centre Mémoire (CMRR) de StrasbourgHôpital Universitaire StrasbourgStrasbourgFrance
  11. 11.Centre Mémoire (CMRR) de ToursHôpital Universitaire ToursToursFrance
  12. 12.Centre Mémoire (CMRR) de MontpellierHôpital Universitaire MontpellierMontpellierFrance
  13. 13.Centre Mémoire (CMRR) de LyonHôpital Universitaire LyonLyonFrance

Personalised recommendations